The stock of Charles River Laboratories International Inc (NYSE: CRL) has decreased by -4.67 when compared to last closing price of 206.54.Despite this, the company has seen a loss of -6.37% in its stock price over the last five trading days. zacks.com reported 2024-11-11 that Explore how Charles River’s (CRL) revenue from international markets is changing and the resulting impact on Wall Street’s predictions and the stock’s prospects.
Is It Worth Investing in Charles River Laboratories International Inc (NYSE: CRL) Right Now?
Charles River Laboratories International Inc (NYSE: CRL) has a price-to-earnings ratio that is above its average at 24.31x. The stock has a 36-month beta value of 1.39. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 5 as “overweight,” 8 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRL is 50.58M, and at present, short sellers hold a 3.66% of that float. On November 15, 2024, the average trading volume of CRL was 688.42K shares.
CRL’s Market Performance
CRL stock saw an increase of -6.37% in the past week, with a monthly gain of 0.92% and a quarterly increase of -2.46%. The volatility ratio for the week is 4.40%, and the volatility levels for the last 30 days are 3.58% for Charles River Laboratories International Inc (CRL).. The simple moving average for the past 20 days is 1.16% for CRL’s stock, with a -10.45% simple moving average for the past 200 days.
Analysts’ Opinion of CRL
Many brokerage firms have already submitted their reports for CRL stocks, with CLSA repeating the rating for CRL by listing it as a “Hold.” The predicted price for CRL in the upcoming period, according to CLSA is $205 based on the research report published on November 07, 2024 of the current year 2024.
CLSA, on the other hand, stated in their research note that they expect to see CRL reach a price target of $167. The rating they have provided for CRL stocks is “Underperform” according to the report published on October 23rd, 2024.
CRL Trading at 0.84% from the 50-Day Moving Average
After a stumble in the market that brought CRL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.40% of loss for the given period.
Volatility was left at 3.58%, however, over the last 30 days, the volatility rate increased by 4.40%, as shares sank -0.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.99% upper at present.
During the last 5 trading sessions, CRL fell by -6.37%, which changed the moving average for the period of 200-days by -8.96% in comparison to the 20-day moving average, which settled at $194.64. In addition, Charles River Laboratories International Inc saw -16.71% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRL starting from WALLMAN RICHARD F, who sale 6,621 shares at the price of $216.12 back on Nov 07 ’24. After this action, WALLMAN RICHARD F now owns 12,386 shares of Charles River Laboratories International Inc, valued at $1,430,918 using the latest closing price.
WALLMAN RICHARD F, the Director of Charles River Laboratories International Inc, sale 1,000 shares at $216.50 during a trade that took place back on Nov 07 ’24, which means that WALLMAN RICHARD F is holding 0 shares at $216,500 based on the most recent closing price.
Stock Fundamentals for CRL
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.34 for the gross margin
The net margin for Charles River Laboratories International Inc stands at 0.1. The total capital return value is set at 0.08. Equity return is now at value 11.81, with 5.36 for asset returns.
Based on Charles River Laboratories International Inc (CRL), the company’s capital structure generated 0.38 points at debt to capital in total, while cash flow to debt ratio is standing at 0.34. The debt to equity ratio resting at 0.62. The interest coverage ratio of the stock is 4.28.
Currently, EBITDA for the company is 1.03 billion with net debt to EBITDA at 2.57. When we switch over and look at the enterprise to sales, we see a ratio of 3.11. The receivables turnover for the company is 5.38for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.48.
Conclusion
To sum up, Charles River Laboratories International Inc (CRL) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
